New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 24, 2012
10:25 EDTAKS, MU, NICE, PROV, QCOR, RBC, SQNM, X, VECO, MRX, IEX, ATU, ATML, BAX, CCI, FNSR, FCF, FLS, GRC, WBSOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AK Steel (AKS) downgraded to Sell from Neutral at Citigroup... Actuant (ATU) downgraded to Hold from Buy at Jefferies... Atmel (ATML) downgraded to Neutral from Buy at UBS... Baxter (BAX) downgraded to Hold from Buy at Deutsche Bank... Crown Castle (CCI) downgraded to Neutral from Outperform at Macquarie... Finisar (FNSR) downgraded to Market Perform from Outperform at Raymond James... First Commonwealth (FCF) downgraded to Market Perform at Keefe Bruyette... Flowserve (FLS) downgraded to Hold from Buy at Jefferies... Gorman-Rupp (GRC) downgraded to Underperform from Hold at Jefferies... IDEX Corp. (IEX) downgraded to Hold from Buy at Jefferies... Medicis (MRX) downgraded to Neutral from Positive at Susquehanna... Micron (MU) downgraded to Sector Perform from Outperform at Pacific Crest... NICE Systems (NICE) downgraded to Sector Perform from Outperform at RBC Capital... Providen (PROV) downgraded to Market Perform from Outperform at Raymond James... Questcor (QCOR) downgraded to Market Perform from Outperform at Leerink... Regal-Beloit (RBC) downgraded to Hold from Buy at Jefferies... Sequenom (SQNM) downgraded to Neutral from Overweight at Piper Jaffray... U.S. Steel (X) downgraded to Neutral from Buy at Citigroup... Veeco (VECO) downgraded to Sell from Neutral at Goldman... Webster Financial (WBS) downgraded to Underweight from Equal Weight at Morgan Stanley.
News For AKS;ATU;ATML;BAX;CCI;FNSR;FCF;FLS;GRC;IEX;MRX;MU;NICE;PROV;QCOR;RBC;SQNM;X;VECO;WBS From The Last 14 Days
Check below for free stories on AKS;ATU;ATML;BAX;CCI;FNSR;FCF;FLS;GRC;IEX;MRX;MU;NICE;PROV;QCOR;RBC;SQNM;X;VECO;WBS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 24, 2014
21:54 EDTSQNMPiper Jaffray to hold a bus tour
Subscribe for More Information
August 22, 2014
12:22 EDTXU.S. Steel CEO comments on affirmative decision by ITC in OCTG trade case
United States Steel President and CEO Mario Longhi issued the following statement in response to the International Trade Commission's affirmative final vote in a trade case on Oil Country Tubular Goods against eight countries including South Korea. The company, the largest integrated producer of tubular products headquartered in the United States, was a petitioner in the case. Longhi's statement follows: "United States Steel Corporation is pleased with the International Trade Commission's affirmative final vote to impose anti-dumping orders against six of the nine countries that are dumping Oil Country Tubular Goods into the market. U. S. Steel will continue to evaluate all of its options, including further litigation, with regards to Saudi Arabia, who was excluded from the International Trade Commission's final vote as a result of an amended final determination from the Department of Commerce, and the two countries, Thailand and the Philippines, for which the ITC reached a negative determination. The International Trade Commission's diligent and conscientious investigation and affirmative final vote clearly recognized that these six countries, which represent more than 90% of the unfairly traded imports that entered the U.S. market in 2013, imported OCTG using unfair methods and market distorting pricing. The dumped imports from all nine countries have caused material injury to the American market and the American worker. Orders have been reduced, mills idled and jobs have been lost. We are satisfied that the affirmative vote will ensure a more competitive and fairer OCTG market for American manufacturing and American workers. While U. S. Steel will continue on our own path toward sustainable profitability and to supply our customers with innovative steel solutions, we also intend to seek transformative, meaningful change to our trade laws to ensure that fairness will exist and is preserved, which can lead to a brighter future for American industry."
10:42 EDTAKS, XAnalyst says tariff threat could protect steelmakers
Subscribe for More Information
10:01 EDTAKSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:36 EDTXActive equity options trading on open
Subscribe for More Information
07:01 EDTX, AKSSteel price outlook raised at UBS
Subscribe for More Information
06:43 EDTAKSAK Steel upgraded to Neutral from Sell at UBS
Subscribe for More Information
06:26 EDTAKSAK Steel upgraded to Neutral from Sell at UBS
Subscribe for More Information
August 21, 2014
15:37 EDTBAXNektar: Baxter announces positive results from Phase 3 study of BAX 855
Nektar Therapeutics (NKTR) reports Baxter International (BAX) announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95 percent reduction in median ABR as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes, 96 percent of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 - 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study
10:17 EDTMUStocks with call strike movement; MU HTZ
Subscribe for More Information
09:44 EDTVECOVeeco management to meet with UBS
Subscribe for More Information
09:02 EDTBAXBaxter announces BAX 855 met primary endpoint in Phase 3 study
Baxter announced "positive" results from its Phase 3 pivotal clinical trial of BAX 855, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95% reduction in median ABR as compared to those in the on-demand arm. BAX 855 was also effective in treating bleeding episodes, 96% of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study.
08:14 EDTATMLAtmel, Fairchild potential takeover candidates, says FBR Capital
Subscribe for More Information
06:12 EDTMUDRAM prices making downward correction with oversupply concerns, DigiTimes says
Subscribe for More Information
August 20, 2014
10:04 EDTRBCOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: BHP Billiton (BHP) downgraded to Underperform from Neutral at Credit Suisse... GT Advanced (GTAT) downgraded to Underperform from Outperform at CLSA... Hertz (HTZ) downgraded to Hold from Buy at Deutsche Bank... IDEXX (IDXX) downgraded to Sell from Neutral at Northcoast... Prestige Brands (PBH) downgraded to Neutral from Buy at Sidoti... Real Goods Solar (RGSE) downgraded to Neutral from Buy at Roth Capital... Regal-Beloit (RBC) downgraded to Neutral from Buy at Longbow... SunCoke Energy (SXC) downgraded to Neutral from Outperform at Credit Suisse... Tidewater (TDW) downgraded to Market Perform from Outperform at Clarkson Capital.
09:36 EDTXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL FOLD TSLA TWTR WHX FB TM NFLX X EOG
07:17 EDTRBCRegal-Beloit downgraded to Neutral from Buy at Longbow
Subscribe for More Information
August 19, 2014
16:33 EDTBAXBaxter to expand Alabama facility to increase dialyzers production
Subscribe for More Information
11:32 EDTSQNMLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.
August 15, 2014
06:08 EDTQCORQuestcor implied volatility of 28 at lower end of index mean range
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use